Readthrough-Promoting Drugs Gentamicin and PTC124 Fail to Rescue Na v 1.5 Function of Human-Induced Pluripotent Stem Cell–Derived Cardiomyocytes Carrying Nonsense Mutations in the Sodium Channel Gene SCN5A
- 1 November 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 9 (11)
Abstract
Background—: Several compounds have been reported to induce translational readthrough of premature stop codons resulting in the production of full-length protein by interfering with ribosomal proofreading. Here we examined the effect of 2 of these compounds, gentamicin and PTC124, in human-induced pluripotent stem cell (hiPSC)–derived cardiomyocytes bearing nonsense mutations in the sodium channel gene SCN5A , which are associated with conduction disease and potential lethal arrhythmias. Methods and Results—: We generated hiPSC from 2 patients carrying the mutations R1638X and W156X. hiPSC-derived cardiomyocytes from both patients recapitulated the expected electrophysiological phenotype, as evidenced by reduced Na + currents and action potential upstroke velocities compared with hiPSC-derived cardiomyocytes from 2 unrelated control individuals. While we were able to confirm the readthrough efficacy of the 2 drugs in Human Embryonic Kidney 293 cells, we did not observe rescue of the electrophysiological phenotype in hiPSC-derived cardiomyocytes from the patients. Conclusions—: We conclude that these drugs are unlikely to present an effective treatment for patients carrying the loss-of-function SCN5A gene mutations examined in this study.Keywords
This publication has 36 references indexed in Scilit:
- Therapeutics Based on Stop Codon ReadthroughAnnual Review of Genomics and Human Genetics, 2014
- Comparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndromeInternational Journal of Molecular Medicine, 2013
- Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspectsThe Journal of Physiology, 2013
- Ataluren as an Agent for Therapeutic Nonsense SuppressionAnnual Review of Medicine, 2013
- Sense from nonsense: therapies for premature stop codon diseasesTrends in Molecular Medicine, 2012
- Pharmaceutical therapies to recode nonsense mutations in inherited diseasesPharmacology & Therapeutics, 2012
- Readthrough of long-QT syndrome type 1 nonsense mutations rescues function but alters the biophysical properties of the channelBiochemical Journal, 2012
- Cardiac ion channels in health and diseaseHeart Rhythm, 2010
- Aminoglycoside antibiotics restore functional expression of truncated HERG channels produced by nonsense mutationsHeart Rhythm, 2009
- Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult VolunteersThe Journal of Clinical Pharmacology, 2007